The molecular basis of type 1 glycogen storage diseases
- PMID: 11899241
- DOI: 10.2174/1566524013364112
The molecular basis of type 1 glycogen storage diseases
Abstract
Glycogen storage disease type 1 (GSD-1), also known as von Gierke disease, is a group of autosomal recessive metabolic disorders caused by deficiencies in the activity of the glucose-6-phosphatase (G6Pase) system that consists of at least two membrane proteins, glucose-6-phosphate transporter (G6PT) and G6Pase. G6PT translocates glucose-6-phosphate (G6P) from cytoplasm to the lumen of the endoplasmic reticulum (ER) and G6Pase catalyzes the hydrolysis of G6P to produce glucose and phosphate. Therefore, G6PT and G6Pase work in concert to maintain glucose homeostasis. Deficiencies in G6Pase and G6PT cause GSD-1a and GSD-1b, respectively. Both manifest functional G6Pase deficiency characterized by growth retardation, hypoglycemia, hepatomegaly, kidney enlargement, hyperlipidemia, hyperuricemia, and lactic acidemia. GSD-1b patients also suffer from chronic neutropenia and functional deficiencies of neutrophils and monocytes, resulting in recurrent bacterial infections as well as ulceration of the oral and intestinal mucosa. The G6Pase gene maps to chromosome 17q21 and encodes a 36-kDa glycoprotein that is anchored to the ER by 9 transmembrane helices with its active site facing the lumen. Animal models of GSD-1a have been developed and are being exploited to delineate the disease more precisely and to develop new therapies. The G6PT gene maps to chromosome 11q23 and encodes a 37-kDa protein that is anchored to the ER by 10 transmembrane helices. A functional assay for the recombinant G6PT protein has been established, which showed that G6PT functions as a G6P transporter in the absence of G6Pase. However, microsomal G6P uptake activity was markedly enhanced in the simultaneous presence of G6PT and G6Pase. The cloning of the G6PT gene now permits animal models of GSD-1b to be generated. These recent developments are increasing our understanding of the GSD-l disorders and the G6Pase system, knowledge that will facilitate the development of novel therapeutic approaches for these disorders.
Similar articles
-
Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.Curr Mol Med. 2002 Mar;2(2):121-43. doi: 10.2174/1566524024605798. Curr Mol Med. 2002. PMID: 11949931 Review.
-
Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.J Inherit Metab Dis. 2015 May;38(3):511-9. doi: 10.1007/s10545-014-9772-x. Epub 2014 Oct 7. J Inherit Metab Dis. 2015. PMID: 25288127 Review.
-
Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.Nat Rev Endocrinol. 2010 Dec;6(12):676-88. doi: 10.1038/nrendo.2010.189. Epub 2010 Oct 26. Nat Rev Endocrinol. 2010. PMID: 20975743 Free PMC article. Review.
-
Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.Hepatology. 2012 Nov;56(5):1719-29. doi: 10.1002/hep.25717. Epub 2012 Aug 27. Hepatology. 2012. PMID: 22422504 Free PMC article.
-
Molecular biology and gene therapy for glycogen storage disease type Ib.J Inherit Metab Dis. 2018 Nov;41(6):1007-1014. doi: 10.1007/s10545-018-0180-5. Epub 2018 Apr 16. J Inherit Metab Dis. 2018. PMID: 29663270 Review.
Cited by
-
Infections in patients with inherited defects in phagocytic function.Clin Microbiol Rev. 2003 Oct;16(4):597-621. doi: 10.1128/CMR.16.4.597-621.2003. Clin Microbiol Rev. 2003. PMID: 14557288 Free PMC article. Review.
-
Kidney and Metabolic Phenotypes in Glycogen Storage Disease Type-I Patients.Front Pediatr. 2020 Sep 11;8:591. doi: 10.3389/fped.2020.00591. eCollection 2020. Front Pediatr. 2020. PMID: 33042926 Free PMC article.
-
Molecular mechanisms of aberrant neutrophil differentiation in glycogen storage disease type Ib.Cell Mol Life Sci. 2022 Apr 18;79(5):246. doi: 10.1007/s00018-022-04267-5. Cell Mol Life Sci. 2022. PMID: 35437689 Free PMC article.
-
Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels.J Allergy Clin Immunol. 2014 May;133(5):1410-9, 1419.e1-13. doi: 10.1016/j.jaci.2014.02.025. Epub 2014 Apr 1. J Allergy Clin Immunol. 2014. PMID: 24698316 Free PMC article. Clinical Trial.
-
Biochemical and clinical aspects of glycogen storage diseases.J Endocrinol. 2018 Sep;238(3):R131-R141. doi: 10.1530/JOE-18-0120. Epub 2018 Jun 6. J Endocrinol. 2018. PMID: 29875163 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources